The role of vitamin D supplementation in augmenting IFN-γ production in response to mycobacterium tuberculosis Infection: A randomized controlled trial.
Study Goal
The researchers aimed to determine whether vitamin D supplementation improves the prognosis of tuberculosis (TB) patients by influencing immune responses and clinical outcomes.
Results Summary
Vitamin D supplementation led to significant weight gain, reduced lung disease persistence, a 50% decrease in cavity size, and increased IFN-γ production in patients with low baseline vitamin D levels. The findings suggest therapeutic benefits of vitamin D in TB management.
Population
200 TB patients (106 received vitamin D, 94 received placebo).
Effective Dosage
400,000 IU of injectable vitamin D3, administered in 2 doses.
Duration
3 months (assessed monthly).
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
Vitamin D | decrease | Interferon-gamma (IFN-γ) and lowering host inflammation | - | - | supports the immune system fight TB by inhibiting | #1 |
400,000 IU of injectable vitamin D3 | increase | weight | TB patients | +3.90 pounds | gained significantly more weight | #2 |
400,000 IU of injectable vitamin D3 | decrease | persistent lung disease zones | TB patients | 1.33 zones vs. 1.84 zones | had less persistent lung disease on imaging | #3 |
400,000 IU of injectable vitamin D3 | decrease | cavity size | TB patients | 50% | had a 50% decrease in | #4 |
vitamin D supplements | increase | MTB-induced IFN-γ production | patients with low baseline serum concentrations of 25-(OH)D | - | had a significant increase in | #5 |
Vitamin D administration in large amounts | increase | TB patients | TB patients | - | can hasten the recovery of | #6 |
Vitamin D supports the immune system fight TB by inhibiting Interferon-gamma (IFN-γ) and lowering host inflammation. The purpose of the research was to see if giving the vitamin D supplements to TB patients affected their prognosis. A randomized placebo control study of 200 TB patients was performed among which 106 received 400,000 IU of injectable vitamin D3 and 94 received placebo for 2 doses. Assessment was carried out at the end of every month for 3 months. IFN-γ responses to whole blood stimulation generated by the Mycobacterium tuberculosis sonicate (MTBs) antigen and early secreted and T cell activated 6 kDa (ESAT6) were assessed at 0 and 12 weeks. The statistical analysis used descriptive statistics (mean and standard deviation), Friedman's test and Fisher's test. The vitamin D group gained significantly more weight (+3.90 pounds) and had less persistent lung disease on imaging (1.33 zones vs. 1.84 zones). They also had a 50% decrease in cavity size. Additionally, patients with low baseline serum concentrations of 25-(OH)D had a significant increase in MTB-induced IFN-γ production after taking vitamin D supplements. Vitamin D administration in large amounts can hasten the recovery of TB patients. The findings point is a therapeutically useful activity of Vitamin D's in the management for tuberculosis.